EGFR Positive Lung Cancer UK· @EgfrUk · X·· 1 天前评分70
正文 · 原文
What happens when osimertinib stops working? A major concern for our EGFR+ #lungcancer community.
SAFFRON Phase III: 17.8 vs 12.9 months median survival with osimertinib + savolitinib vs chemotherapy in MET-altered disease.
Promising results #ESMO2026. Now, what about UK access?
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335 #LCSM
9 浏览 · 1 赞 · 0 转发 · 0 回复
来源：EGFR Positive Lung Cancer UK · x.com